DiaMedica

About:

DiaMedica is a biopharmaceutical company that focuses on developing treatments for stroke.

Twitter/X: diamedica

Top Investors: Fosun Pharma, SK Group, Genesys Venture, Hermed Capital

Description:

DiaMedica is a biopharmaceutical company that focuses on developing treatments for stroke and other vascular diseases where no current therapies are available. The company's treatments primarily focus on on chronic kidney disease and acute ischemic stroke. Its pipeline product, DM199, is a recombinant form of human tissue kallikrein-1.

Total Funding Amount:

$137M

Estimated Revenue Range:

$1M to $10M

Headquarters Location:

Minneapolis, Minnesota, United States

Founded Date:

2000-01-01

Contact Email:

info(AT)diamedica.com

Founders:

Wayne Lautt

Number of Employees:

11-50

Last Funding Date:

2024-06-26

IPO Status:

Public

Industries: